Mainz, September 7, 2018 – TRON is thrilled to announce an article co-authored by Mustafa Diken and Lina Hilscher in the journal EJNMMI Research (European Journal of Nuclear Medicine and Molecular Imaging Research).
In collaboration with Dr. Matthias Miederer’s group in the Department of Nuclear Medicine at the University Medical Center Mainz, TRON scientists contributed in showing that FDG-PET can be used for in vivo imaging of the immune response to systemic RNA vaccination. The article describes rapid and transient vaccination-induced increase of FDG uptake within the spleen, reflecting immune activation preceding T-cell proliferation. This finding shows the potential of FDG-PET/CT as a new application to image immune processes in the search for new therapies.
You can read the article here.
Mainz, September 6, 2018 - The University Cancer Center at the University Mainz is host to their 1st Science Day 2018 on September 6th 2018. The event features a variety of young investigators and established scientists presenting their research in the fields of cancer immunotherapy, genetic instability, epidemiology, or drug delivery.
Our doctoral student Nadja Salomon will present her combination therapy studies using local radiotherapy and E7-RNA-LPX vaccination. She will give a talk during the session "Tumor Immunology/Cancer Immunotherapy" at 9:40 a.m.. At 3:20 p.m., Mustafa Diken will give his talk "Delivering the Messenger for Cancer Immunity" in the session "Drug delivery".
The programm concludes with a lecture by Prof. Dr. Margret Shipp from the Harvard Medical School and Dana Faber Cancer Center in Boston, USA, as part of the Mildred Scheel Lecture series. The Keynote Lecture entitled "Targetable Genetic Signatures in Lymphoid Malignancies" will start 4:30 p.m..
Mainz, August 22, 2018 - The Center for Thrombosis and Hemostasis (CTH) at the University Medical Center Mainz is host to a new Innovative Training Network (ITN) „TICARDIO – Thrombo-Inflammation in Cardiovascular Disease“. It will address the studies of pathological processes in cardiovascular diseases. The ITN offers 15 science graduate students the opportunity to develop scientific and general skills within a cross-border network. The structured international, interdisciplinary, and intersectoral research and training program will take place from 2019 at Mainz, Maastricht, Marseille, and Dortmund. The European Commission is providing 4 million euros to ITN under the Marie Skłodowska Curie Action (MSCA) for 48 months through its Horizon 2020 Framework Program for Research and Innovation. As part of the doctoral training program, TRON participates as an external institution in which the doctoral students can gain non-academic experience.
Further information can be found in the official press release.
Mainz, August 10, 2018 - The new Helmholtz Institute "HI-TRON Mainz" aims to develop effective immunotherapies and identify new biomarkers for cancer treatments.
HI-TRON is a collaboration between the German Cancer Research Center (DKFZ) and the research institute TRON - Translational Oncology at the University Medical Center of Johannes Gutenberg University Mainz. Cooperation agreements have now been signed.
"By founding of HI-TRON Mainz, we are pursuing the mission of establishing a world-leading center for personalized cancer immunotherapy. HI-TRON Mainz thus engenders the Helmholtz spirit by acting as a catalyst for groundbreaking technologies, sustainable translation of academic innovation and its clinical implementation for the benefit of patients, "so Ugur Sahin, founder and scientific director of TRON.
Mainz, August 10, 2018 – TRON is delighted to announce a Comment authored by Özlem Türeci and Ugur Sahin in the journal Nature Biomedical Engineering.
“Challenges towards the realization of individualized cancer vaccines” discusses the challenges of optimizing vaccine design, manufacturing and affordability, and identifying the most suitable clinical setting(s). TRON colleagues Martin Löwer, Barbara Schrörs and Arbel Tadmor are co-authors.
You can access this article via this link.
Mainz - TRON (Translational Oncology at the University Medical Center of the Johannes Gutenberg-University Mainz), a non-profit organization and internationally recognized leader in tumor immunology and cancer therapy research, has entered into a research collaboration with Astellas Pharma Inc., a company dedicated to improving the health of people through the provision of innovative and reliable pharmaceutical products.
“We are excited to collaborate with Astellas Pharma Inc. which highlights the quality of our research in oncology,” said Michael Foehlings, Managing Director of TRON. “Collaborations with key players in the pharmaceutical industry provide an excellent platform for the dissemination of research performed at TRON to address an unmet medical need and to improve patients’ lives."
TRON in the Media
Welcome to TRON
TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz is a biopharmaceutical research organization that pursues new diagnostics and drugs for the treatment of cancer and other severe diseases with high medical need. A focus of TRON is the development of novel platforms for individualized therapies and biomarkers, translating basic research into drug applications. TRON partners with academic institutions, biotech companies and the pharmaceutical industry, executing research with leading-edge technologies and supporting the development of innovative drugs to promote human health.